DNA甲基化作为诊断标记物在胰腺癌诊断中的研究进展

Reaserch progress on the application of DNA methylation as a biomarker in diagnosis of pancreatic cancer

胰腺癌是临床上常见预后不良的恶性肿瘤之一。目前关于胰腺癌发病的相关分子机制尚未完全的阐明,这在很大程度阻碍了胰腺癌的诊断及治疗方面的发展。表观遗传学改变在肿瘤的发生发展机制中起着重要的作用,而DNA甲基化是主要的表观遗传学修饰之一。异常的启动子DNA甲基化可以出现在胰腺癌的各个阶段,而且能在患者的血浆或血清标本中检测到这些异常变化。该文总结了近年来关于DNA甲基化在胰腺癌诊断方面的研究进展,旨在讨论DNA甲基化在胰腺癌诊断中的价值。

Pancreatic cancer is one of common malignancies with poor clinical prognosis. Currently,the molecular mechanism of pancreatic cancer remains elusive,which severely hinders the diagnosis and treatment of pancreatic carcinoma. The epigenetic modifications play a pivotal role in the occurrence and progression of malignant tumors and DNA methylation is one of the major epigenetic modifications. Aberrant promoter DNA methylation can be observed in each stage of pancreatic cancer. Such abnormalities can be detected in patients' plasma or serum samples. In this paper,recent research progress on the application of DNA methylation in the diagnosis of pancreatic carcinoma was briefly reviewed,aiming to evaluate the clinical significance of DNA methylation in diagnosing pancreatic cancer.